Up next

Autoplay

Could the Combo Daratumumab, Pomalidomide, and Dexamethasone Be Used in an Earlier Line of Therapy?

2 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens in Greece, discusses outcomes from the phase III APOLLO, presented at the ASH Annual Meeting & Exposition, that assessed the efficacy of the addition of daratumumab to pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Show more
0 Comments sort Sort By

Up next

Autoplay